{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:21:30Z","timestamp":1791321690771,"version":"4.3.1"},"reference-count":8,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Omadacycline (OMC), a broad-spectrum aminomethylcycline, has shown clinical efficacy in anaerobic acute bacterial skin and skin structure infections (ABSSSI) and in animal models of intra-abdominal anaerobic infections. Here, the\n            <jats:italic>in vitro<\/jats:italic>\n            activity of OMC against clinically relevant anaerobes was similar to that of tigecycline, with MIC\n            <jats:sub>90<\/jats:sub>\n            values of 1 to 8 \u03bcg\/ml against\n            <jats:named-content content-type=\"genus-species\">Bacteroides<\/jats:named-content>\n            spp., 0.5 \u03bcg\/ml against\n            <jats:named-content content-type=\"genus-species\">Clostridium difficile<\/jats:named-content>\n            ,\n            <jats:named-content content-type=\"genus-species\">Prevotella<\/jats:named-content>\n            spp., and\n            <jats:named-content content-type=\"genus-species\">Porphyromonas asaccharolytica<\/jats:named-content>\n            , 1 \u03bcg\/ml against\n            <jats:named-content content-type=\"genus-species\">Peptostreptococcus<\/jats:named-content>\n            spp., and 16 \u03bcg\/ml against\n            <jats:named-content content-type=\"genus-species\">Clostridium perfringens<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.00047-18","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T14:38:29Z","timestamp":1518100709000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":31,"title":["<i>In Vitro<\/i>\n            Activities of Omadacycline and Comparators against Anaerobic Bacteria"],"prefix":"10.1128","volume":"62","author":[{"given":"Laure","family":"Stapert","sequence":"first","affiliation":[{"name":"Micromyx, Inc., Kalamazoo, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Micromyx, Inc., Kalamazoo, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Shinabarger","sequence":"additional","affiliation":[{"name":"Micromyx, Inc., Kalamazoo, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marra","sequence":"additional","affiliation":[{"name":"Micromyx, Inc., Kalamazoo, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Pillar","sequence":"additional","affiliation":[{"name":"Micromyx, Inc., Kalamazoo, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.10.010"},{"key":"e_1_3_2_3_2","first-page":"2810","volume-title":"Principles and practice of infectious disease","author":"Tzianabos AO","year":"2005","unstructured":"Tzianabos AO, Kasper DL. 2005. Anaerobic infections: general concepts, p 2810\u20132816. In Mandell GL, Bennett JE, Dolin R (ed), Principles and practice of infectious disease, 6th ed. Elsevier Saunders, Philadelphia, PA.","edition":"6"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_2_5_2","volume-title":"Efficacy of oral and IV omadacycline vs. linezolid for treating adult subjects with ABSSSI: analysis by infection type and pathogen in the oasis study","author":"O'Riordan W","year":"2017","unstructured":"O'Riordan W, Green S, Overcash JS, Eckburg P, Steenburgen J, Das A, Tzanis E, Garrity-Ryan L, Manley A, Villano S, Loh E. 2017. Efficacy of oral and IV omadacycline vs. linezolid for treating adult subjects with ABSSSI: analysis by infection type and pathogen in the oasis study. Poster presentation P1252. European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria."},{"key":"e_1_3_2_6_2","volume-title":"BAY 73-7388 is highly efficacious in animal models of intra-abdominal infections caused by a range of aerobic and anaerobic organisms, including VRE","author":"Endermann R","year":"2004","unstructured":"Endermann R, Ladel CH, Broetz-Oesterhelt H, Labischinski H. 2004. BAY 73-7388 is highly efficacious in animal models of intra-abdominal infections caused by a range of aerobic and anaerobic organisms, including VRE. Poster P928. European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic."},{"key":"e_1_3_2_7_2","volume-title":"CLSI document M11-A8","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. Methods for dilution antimicrobial susceptibility testing of anaerobic bacteria; approved standard\u2014eighth edition. CLSI document M11-A8. CLSI, Wayne, PA."},{"key":"e_1_3_2_8_2","volume-title":"CLSI document M100-S26","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement. CLSI document M100-S26. CLSI, Wayne, PA."},{"key":"e_1_3_2_9_2","volume-title":"Tygacil prescribing information","author":"Wyeth Pharmaceuticals Inc","year":"2016","unstructured":"Wyeth Pharmaceuticals Inc. 2016. Tygacil prescribing information. Wyeth Pharmaceuticals Inc., Philadelphia, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00047-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00047-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:13:33Z","timestamp":1645478013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00047-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1128\/AAC.00047-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.00047-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"2018-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00047-18"}}